Healthcare

Tim Shannon

General Partner / East Coast

Since 2009

Tim pairs his operating experience and medical background to create value for companies from the earliest stage through FDA approval. Prior to becoming an investor, Tim was president and chief executive officer of CuraGen, a publicly traded biopharmaceutical company focused on oncology. He began his career as a pulmonary and critical care physician. Tim earned his medical degree from the University of Connecticut and has a B.A. in chemistry from Amherst College.

Tim in 5

Travel: Did it early in life - I like New England now!

Sport: UCONN Basketball

Family: Large

AccomplishmentsL Raising 5 children (a work in progress)

Bucket List: Completing 10th marathon

Investments

Current

Previous

  • Civitas Therapeutics
    Acquired by Acorda Therapeutics
  • CytomX
    IPO
  • Novira Therapeutics
    Acquired by Johnson & Johnson

Latest

Tim Shannon in BioCentury: Making orphan drug prices work for society

Endpoints News: Four biotechs, including NextCure, haul in $303M+ from a fresh burst of IPOs

Business Insider: Scientists are working on cancer treatments that attack the disease's 'Holy Grail"

Nature: Protein-slaying drugs could be the next blockbuster therapies

Nature Reviews: First targeted protein degrader, developed by Arvinas, hits the clinic

Nasdaq: Cancer biotech Arvinas prices upsized IPO at $16

Tim Shannon: More hope for cystic fibrosis treatment, and still more to do

Scientific American: New thalidomide-like therapy hijacks cells’ trash-disposal system

Fierce Biotech: Mackay’s Rallybio rare disease startup raises $37M in first funding round

IDEAYA & the Next Frontier in Synthetic Lethality

FierceBiotech: GV, Roche help Ideaya to $94M crossover round, setting stage for synthetic lethality, I-O trials

FierceBiotech: Arvinas in $830M-plus Pfizer biobucks deal

BioCentury Innovations: How Vivace turns the YAP pathway off or on to treat cancer

Endpoints News: Genentech inks $650M deal with protein degradation pioneer Arvinas

Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets

Fierce Biotech: Vivace uncloaks with $40M, U.S./China backing for cancer trials

Endpoints: Canaan reels in a jumbo $800 million with a big focus on a new wave of startups

STAT: Forget the science. These investors think they can pick biotech winners by algorithm

Tim Shannon: Durable bonds and the birth of Vivace Therapeutics

Tim in 5

Travel: Did it early in life - I like New England now!

Sport: UCONN Basketball

Family: Large

AccomplishmentsL Raising 5 children (a work in progress)

Bucket List: Completing 10th marathon